<DOC>
	<DOCNO>NCT00262951</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Radiation therapy use high-energy x-ray kill tumor cell . Interferon alfa may interfere growth tumor cell . Giving combination chemotherapy radiation therapy together interferon alfa surgery may shrink tumor remove . Giving chemotherapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give combination chemotherapy radiation therapy together interferon alfa work treat patient locally advanced pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Chemoradiation Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effect neoadjuvant chemoradiotherapy interferon alfa convert patient locally advance unresectable adenocarcinoma pancreas resectability . Secondary - Determine rate severity early late toxic effect regimens patient . - Improve surgical morbidity profile overall survival patient undergo surgical resection . - Determine overall progression-free survival patient treat regimen . OUTLINE : This pilot , single center study . - Part 1 ( neoadjuvant therapy ) : Patients receive fluorouracil IV continuously 24 hour day 1-38 ; cisplatin IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 ; interferon alfa subcutaneously day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 , 29 , 31 , 33 , 36 , 38 . Patients also undergo radiotherapy day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-38 . Patients undergo restaging . Patients resectable disease undergo surgery , 4-10 week later , proceed part 2 . Patients unresectable disease proceed directly part 2 , 4 week completion neoadjuvant therapy . - Part 2 ( chemotherapy ) : Patients receive fluorouracil IV day 1 , 8 , 15 , 22 , 29 , 36 . Treatment repeat every 56 day 2 course absence disease progression unacceptable toxicity . Patients unresectable disease undergo restaging course fluorouracil . If tumor subsequently become resectable , patient undergo surgery . After completion study treatment , patient follow periodically 5 year annually thereafter .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patient must newly diagnose computated tomography ( CT ) endoscopic ultrasound ( EUS ) stage Tx4 , N01 , M0 adenocarcinoma pancreas accord American Joint Committee Cancer ( AJCC ) stag system . The follow cell type NOT eligible : adenosquamous carcinoma , ampullary carcinoma , carcinoid tumor , cystadenocarcinoma , cystadenoma , distal common bile duct carcinoma , duodenal carcinoma , islet cell carcinoma Treatment must begin within 60 day diagnosis Must locally advance inoperable pancreatic cancer metastatic spread determine baseline diagnostic CT scan chest , endoscopic ultrasound CT scan intravenous ( IV ) contrast ( MRI ) abdomen/pelvis , within 30 day prior registration . No prior systemic chemotherapy radiation therapy pancreatic cancer Documented Eastern Cooperative Oncology Group ( ECOG/Zubrod ) performance status 01 within 14 day prior registration Adequate hematologic , renal hepatic function define follow laboratory value ( complete within 14 day prior registration ) white blood cell ( WBC ) &gt; 3,000 mm3 absolute neutrophil count ( ANC ) &gt; 1,500 mm3 platelet count ≥ 100,000 mm3 hemoglobin &gt; 9.5 g/dl serum creatinine &lt; 1.5 time institutional upper limit normal ( ULN ) total bilirubin ≤ 3 mg/dl AST ( SGOT ) &lt; 4.0 time institutional ULN ALT ( SGPT ) &lt; 4.0 time institutional ULN alkaline phosphatase &lt; 2.0 time institutional ULN Age ≥ 18 year Life expectancy ≥ 12 week Patient ( male female ) reproductive potential require use medically acceptable contraception treatment 3 month last dose chemotherapy . Not pregnant breastfeed since drug use study Pregnancy Category D : Clear evidence risk pregnancy . A negative pregnancy test require within 7 day registration pre perimenopausal ( i.e. , last menstrual period within one year registration ) If patient previous diagnosis cancer , follow criterion must meet documented patient 's medical record : Patient undergone potentially curative therapy prior malignancy . No evidence prior malignancy least 5 year ( except successfully treat cervical carcinoma situ , carcinoma situ breast , nonmelanoma skin cancer . No evidence recurrence prior malignancy . Patient receive chronic immunotherapy ( e.g . prednisone methotrexate ) collagen vascular disease chronic immunologic abnormality eligible . Not require one contraindicated medication Patient must able understand potential risk benefit associate study . Patient able give inform consent would likely comply study parameter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>